Masimo Co. (NASDAQ:MASI) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Masimo Co. (NASDAQ:MASI) has received an average rating of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $144.67.

MASI has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Friday. Piper Sandler boosted their target price on Masimo from $160.00 to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th.

Institutional Trading of Masimo

Several institutional investors and hedge funds have recently bought and sold shares of MASI. Riverview Trust Co acquired a new stake in Masimo in the first quarter valued at $25,000. GAMMA Investing LLC grew its holdings in Masimo by 75.0% during the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 111 shares during the period. EverSource Wealth Advisors LLC increased its position in Masimo by 851.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 295 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 264 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 200 shares during the period. Finally, Parallel Advisors LLC lifted its position in shares of Masimo by 48.3% in the fourth quarter. Parallel Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $52,000 after buying an additional 145 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

Masimo Stock Up 8.7 %

Shares of MASI opened at $121.42 on Monday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.15 and a current ratio of 2.09. Masimo has a 52 week low of $75.22 and a 52 week high of $153.93. The firm has a market capitalization of $6.46 billion, a price-to-earnings ratio of 82.60 and a beta of 0.98. The business’s fifty day moving average price is $115.01 and its two-hundred day moving average price is $124.98.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.09. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The company had revenue of $496.30 million for the quarter, compared to the consensus estimate of $493.92 million. During the same quarter in the prior year, the business posted $0.62 EPS. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. On average, analysts predict that Masimo will post 3.87 earnings per share for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.